While COVID-19 has been an overall negative for most companies, others have benefited.
It was a broad list of stocks including tele-health plays, hand sanitiser manufacturers, tech stocks winning government contracts and biotechs testing their drugs against the virus.
As of right now, a portfolio of all these stocks would have returned 137 per cent in the last 12 months and 43 per cent in the last 6.
But the overall numbers of winners and losers are almost dead level, and only 7 of the 25 stocks on our list have seen gains of over 100 per cent over the past year.
The Magnificent Seven
The biggest gainer is hand sanitiser maker Zoono (ASX:ZNO), up nearly 3000 per cent in a year.
Zoono and its peer Holista Colltech (ASX:HCT) both reported exponential demand for their hand sanitisers as COVID-19 broke out initially in Asia.
Holista, however, is only up 14 per cent on a yearly basis and has retreated in recent days after encountering supply chain issues.
Mesoblast is the world’s biggest listed stem-cell play, but it is testing its treatment on acute respiratory distress syndrome (Ards), the largest cause of death with COVID-19.
This is in addition to stem-cell clinical trials on chronic heart failure and lower back pain — both of which are expected this quarter.
PharmAust is trialling its cancer-fighting monepantel drug against COVID-19. For both diseases, it inhibits a signalling pathway into the cell cycle.
Another biotech on the list is Genetic Signatures (ASX:GSS) (+116%) which developed its own COVID-19 test that is approved in Australia and Europe.
Harris Technology (ASX:HT8) (+192%) was already an online shopping operator, but in April it took the step of launching protective hygiene products including face masks, alcohol wipes and hand sanitisers.
Rounding out the list were clean tech Aeris Environmental (ASX:AEI) (+118%) which has been providing hygiene products and communication automation software stock Whispir (ASX:WSP) (+125%) which has won several public sector contracts during the pandemic.
The post How many stocks fighting COVID-19 have maintained their momentum? appeared first on Stockhead.
Barry Stroman was a reporter for Zerg Watch, before becoming the lead editor. Barry has previously worked for Wired, MacWorld, PCWorld, and VentureBeat covering countless stories concerning all things related to tech and science. Barry studied at NYU.